Literature DB >> 36246755

How to do it? Transcatheter correction of superior sinus venosus defects.

Kothandam Sivakumar1.   

Abstract

Superior sinus venosus defect is characterized by varying degrees of override of the atrial septum by the superior vena cava and anomalous right upper pulmonary vein (RUPV) drainage. The defect is seen posterosuperior to the oval fossa and is traditionally corrected by a surgical patch that routes the anomalously draining RUPV to the left atrium. A few postoperative patients develop stenosis or occlusion of the caval or pulmonary vein and/or sick sinus syndrome secondary to vascular injury. This has kindled a recent interest in nonsurgical correction of these defects by the use of a covered stent to reroof the defect. The complex anatomy of this defect often necessitates the use of advanced imaging tools and postprocessing. Countries with restricted resources do not have easy access to technologies such as three-dimensional printed models and advanced processing like virtual reality or holography. This "How to do it?" article, applicable in these countries, explains the current understanding of this intervention, patient selection, step-by-step explanation of the evaluation, and stent implantation. Copyright:
© 2022 Annals of Pediatric Cardiology.

Entities:  

Keywords:  Anomalous pulmonary vein drainage; balloon interrogation; covered stent; nonsurgical closure; stent exclusion; superior vena cava

Year:  2022        PMID: 36246755      PMCID: PMC9564414          DOI: 10.4103/apc.apc_92_21

Source DB:  PubMed          Journal:  Ann Pediatr Cardiol        ISSN: 0974-5149


  7 in total

1.  Transcatheter closure of sinus venosus atrial septal defect with anomalous drainage of right upper pulmonary vein into superior vena cava--an innovative technique.

Authors:  Gaurav Garg; Himanshu Tyagi; Anil Sivadasan Radha
Journal:  Catheter Cardiovasc Interv       Date:  2014-04-23       Impact factor: 2.692

2.  Sinus Venosus Defects: Anatomic Variants and Transcatheter Closure Feasibility Using Virtual Reality Planning.

Authors:  Animesh Tandon; Barbara E U Burkhardt; Maria Batsis; Thomas M Zellers; Mari Nieves Velasco Forte; Israel Valverde; Ryan P McMahan; Kristine J Guleserian; Gerald F Greil; Tarique Hussain
Journal:  JACC Cardiovasc Imaging       Date:  2018-12-12

3.  Simple Diagnostic Tools May Guide Transcatheter Closure of Superior Sinus Venosus Defects Without Advanced Imaging Techniques.

Authors:  Kothandam Sivakumar; Shakeel Qureshi; Sreeja Pavithran; Sunitha Vaidyanathan; Monica Rajendran
Journal:  Circ Cardiovasc Interv       Date:  2020-11-25       Impact factor: 6.546

4.  Correction of sinus venosus atrial septal defects with the 10 zig covered Cheatham-platinum stent - An international registry.

Authors:  Eric Rosenthal; Shakeel A Qureshi; Matthew Jones; Gianfranco Butera; Kothandam Sivakumar; Younes Boudjemline; Ziyad M Hijazi; Salim Almaskary; Reid D Ponder; Morris M Salem; Kevin Walsh; Damien Kenny; Sebastien Hascoet; Darren P Berman; John Thomson; Joseph J Vettukattil; Evan M Zahn
Journal:  Catheter Cardiovasc Interv       Date:  2021-04-28       Impact factor: 2.692

5.  Evolving surgical strategy for sinus venosus atrial septal defect: effect on sinus node function and late venous obstruction.

Authors:  Robert D Stewart; Frédérique Bailliard; Angela M Kelle; Carl L Backer; Luciana Young; Constantine Mavroudis
Journal:  Ann Thorac Surg       Date:  2007-11       Impact factor: 4.330

6.  Transcatheter Correction of Superior Sinus Venosus Atrial Septal Defects as an Alternative to Surgical Treatment.

Authors:  Jan Hinnerk Hansen; Phuoc Duong; Salim G M Jivanji; Matthew Jones; Saleha Kabir; Gianfranco Butera; Shakeel A Qureshi; Eric Rosenthal
Journal:  J Am Coll Cardiol       Date:  2020-03-24       Impact factor: 24.094

7.  Early experience of transcatheter correction of superior sinus venosus atrial septal defect with partial anomalous pulmonary venous drainage.

Authors:  Mounir Riahi; Mari Nieves Velasco Forte; Nick Byrne; Anthony Hermuzi; Matthew Jones; Alban-Elouen Baruteau; Israel Valverde; Shakeel A Qureshi; Eric Rosenthal
Journal:  EuroIntervention       Date:  2018-10-20       Impact factor: 6.534

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.